EYEG News and Press, Eyegate Pharmaceuticals Inc. From 11/09/20

WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2020 and pr...

WALTHAM, MA / ACCESSWIRE / September 8, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that its Chief Executive Officer, Stephen From, will be presenti...

Gainers:  India Globalization Capital (NYSEMKT: IGC ) +174% . More news on: India Globalization Capital, Inc., Cellular Biomedicine Group, Inc., The Pennant Group, Inc., Stocks on the move, , Read more ...

EyeGate Pharmaceuticals (NASDAQ: EYEG ) +35%  on development path for conjunctivitis treatment. More news on: EyeGate Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Vascular Biogenics Ltd., Stocks on the move, , Read more ...

Thinly traded nano cap EyeGate Pharmaceuticals (NASDAQ: EYEG ) jumps  67%  premarket on light volume in reaction to its announcement that the FDA has clarified a development path for MoxiGel, a combination of its Ocular Bandage Gel and an antibiotic, for the potential treatment...

WALTHAM, MA / ACCESSWIRE / August 12, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback following its pre-IND meeti...

Eyegate Pharmaceuticals (NASDAQ: EYEG ) : Q2 GAAP EPS of -$0.38 beats by $0.05 . More news on: EyeGate Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WALTHAM, MA / ACCESSWIRE / August 6, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended June 30, 2020 and provided ...

The FDA has signed off on filing of an Investigational Device Exemption (IDE) application to commence pivotal study of EyeGate Pharmaceuticals's ( EYEG -1.6% ) lead product candidate, Ocular Bandage Gel eye drop in punctate epitheliopathies (PE). More news on: EyeGate Pharmaceut...

WALTHAM, MA / ACCESSWIRE / July 14, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that based on feedback from a meeting with the U.S. Food and Drug Ad...